This page contains a Flash digital edition of a book.
Table 1 Use of botulinum toxin The range of professionals now treating patients with botulinum toxin aesthetically, represented by current societies and professional bodies in the UK as an example, 2012


Association for Facial Aesthetics (AFA)


British Academy of Aesthetic Dentistry (BAAD)


British Association of Aesthetic Plastic Surgeons (BAAPS)


British Association of Aesthetic, Reconstructive and Plastic Surgeons (BAPRAS)


British Association of Beauty Therapy and Cosmetology (BABTAC)


British Association of Cosmetic Dentistry (BACD)


biological product manufacturing process that quality is built into the entire process—at every stage—and not just ‘tested into the final product’. The overwhelming presence of


quality is a tremendously important and a major aspect of assuring first-class safety of the BoNT products for the patients. This is the top of any quality list and takes precedence over every single aspect of BoNT manufacture. Secondly, the quality systems are there to ensure efficacy of the products, especially in monitoring potential changes over time. A number of BoNT products have been available for over 20 years, a huge timespan over which safety and efficacy must be guaranteed6 And guarantee is the correct


.


word. The manufacturers do all they can, in joint agreement with and


British Association of Cosmetic Nurses (BACN)


British Association of Cosmetic Surgeons (BACS)


British Association of Dermatologists (BAD)


British Cosmetic Dermatology Group (BCDG)


British College of Aesthetic Medicine (BCAM) (formerly British Association of Cosmetic Doctors (BACD))


British Dermatological Nursing Group (BDNG)


British OculoPlastic Surgery Society (BOPSS)


British Society for Dermatological Surgery (BSDS)


National Cosmetology Association (NCA)


Private Independent Aesthetics Practices Association (PIAPA)


Professional Beauty Association (PBA)


6 5 4 3 2 1


0 2006 2007 2008 2009 2010 2011


Figure 1 The steady rise in the use of botulinum toxin for aesthetic treatments in the United States: 25% in 5 years (based on data reported by the American Society of Plastic Surgeons)


prime-journal.com | November/December 2012 ❚ 57


5.4 5 4.1 4.5 4.8


5.7


Millions of BoNT aesthetic treatments


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76